Amundi Purchases 21,783 Shares of Core Laboratories Inc. (NYSE:CLB)

Amundi increased its position in Core Laboratories Inc. (NYSE:CLB) by 194.8% in the 4th quarter, Holdings Channel reports. The firm owned 32,968 shares of the oil and gas company’s stock after buying an additional 21,783 shares during the quarter. Amundi’s holdings in Core Laboratories were worth $600,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of CLB. Assetmark Inc. acquired a new stake in Core Laboratories during the fourth quarter valued at approximately $26,000. Smartleaf Asset Management LLC lifted its position in shares of Core Laboratories by 173.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,037 shares of the oil and gas company’s stock worth $35,000 after buying an additional 1,293 shares during the period. Nisa Investment Advisors LLC boosted its stake in Core Laboratories by 2,688.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,426 shares of the oil and gas company’s stock valued at $42,000 after buying an additional 2,339 shares in the last quarter. Isthmus Partners LLC grew its position in Core Laboratories by 18.8% in the third quarter. Isthmus Partners LLC now owns 10,620 shares of the oil and gas company’s stock valued at $197,000 after acquiring an additional 1,682 shares during the period. Finally, Quantbot Technologies LP acquired a new position in Core Laboratories during the third quarter worth $211,000. Institutional investors and hedge funds own 97.81% of the company’s stock.

Core Laboratories Stock Up 0.2 %

Shares of NYSE CLB opened at $15.40 on Friday. The stock has a market cap of $721.32 million, a PE ratio of 23.34, a PEG ratio of 0.99 and a beta of 2.38. The business has a fifty day moving average of $16.85 and a two-hundred day moving average of $18.21. Core Laboratories Inc. has a 52-week low of $12.95 and a 52-week high of $25.13. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.71 and a current ratio of 2.32.

Core Laboratories (NYSE:CLB) last issued its quarterly earnings data on Wednesday, January 29th. The oil and gas company reported $0.23 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.23. Core Laboratories had a return on equity of 16.24% and a net margin of 5.99%. As a group, equities research analysts expect that Core Laboratories Inc. will post 0.96 earnings per share for the current fiscal year.

Core Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Monday, February 10th were issued a $0.01 dividend. The ex-dividend date was Monday, February 10th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.26%. Core Laboratories’s dividend payout ratio is 6.06%.

Analyst Upgrades and Downgrades

Separately, Citigroup raised Core Laboratories from a “sell” rating to a “neutral” rating and lifted their price objective for the company from $15.00 to $16.00 in a report on Wednesday, March 12th. One analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. According to MarketBeat.com, Core Laboratories currently has an average rating of “Hold” and a consensus price target of $17.50.

Core Laboratories Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.